WSLHD
Skip navigation

Browsing by Author Kariyawasam, Viraj C.

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 20 of 21  next >
PreviewIssue DateTitleAuthor(s)
Cheema-2020-Access to inflammatory bowel disea.pdf.jpg2020Access to inflammatory bowel disease nurses and education is associated with less stress, anxiety, and depression: Australian national inflammatory bowel disease surveyCheema, Madiha; Mitrev, Nikola; Toingson, Maria; Ahlenstiel, Golo; Hall, L.; Kariyawasam, Viraj C.; Cheema, Madiha; Mitrev, Nikola; Toingson, Maria; Ahlenstiel, Golo; Hall, L.; Kariyawasam, Viraj C. 
2023Adolescents and young adults communicating with gastroenterologists: variation in inflammatory bowel disease clinical communicationKarimi, N.; Lukin, A.; Moore, A. R.; Pipicella, J. L.; Kanazaki, R.; Williams, A.; Ng, W.; Kariyawasam, Viraj C.; Mitrev, Nikola; Pandya, Keval V.; Connor, S. J.; Kariyawasam, Viraj C.; Mitrev, Nikola; Pandya, Keval V. 
2011Complete Barretts excision by stepwise endoscopic resection in short-segment disease: Long term outcomes and predictors of strictureChung, A.; Bourke, Michael J.; Hourigan, L. F.; Lim, G.; Moss, A.; Williams, Stephen J.; McLeod, D.; Fanning, S.; Kariyawasam, Viraj C.; Chung, A.; Bourke, Michael J.; Moss, A.; Williams, Stephen J.; McLeod, Duncan; Fanning, S.; Kariyawasam, Viraj C. 
Cheema-2021-Depression, anxiety and stress amo.pdf.jpg2021Depression, anxiety and stress among patients with inflammatory bowel disease during the COVID-19 pandemic: Australian national surveyCheema, Madiha; Mitrev, Nicola; Hall, L.; Tiongson, Maria; Ahlenstiel, Golo; Kariyawasam, Viraj C.; Cheema, Madiha; Mitrev, Nikola; Tiongson, Maria; Ahlenstiel, Golo; Kariyawasam, Viraj C. 
2023Determining efficacy of dynamic multimedia bowel preparation instructions versus standard instructions on adenoma detection and patient reported measures (DIGICLEAN trial): a study protocol for a multicentre, colonoscopist-blinded, randomised controlled trialAu, Michael; Low, P.; Rennie, Michael; Mohseni, Marriam; Song, Yang; Kim, Narae; Baraty, Brandon; Mitrev, Nikola; He, E.; Ho, V.; Leong, R.; Kariyawasam, Viraj C.; Au, Michael; Rennie, Michael; Mohseni, Marriam; Song, Yang; Kim, Narae; Baraty, Brandon; Mitrev, Nikola; Kariyawasam, Viraj C. 
2025Development and validation of a scoring system to predict 2-year clinical remission in ulcerative colitis patients on vedolizumabChaemsupaphan, T.; Pudipeddi, A.; Lin, H.; Paramsothy, S.; Kariyawasam, Viraj C.; Kermeen, M.; Leong, R. W.; Kariyawasam, Viraj C. 
Au-2022-Dual biologic therapy with ocrelizumab.pdf.jpg2022Dual biologic therapy with ocrelizumab for multiple sclerosis and vedolizumab for Crohn's disease: A case report and review of literatureAu, Michael; Mitrev, Nikola; Leong, R. W.; Kariyawasam, Viraj C.; Au, Michael; Mitrev, Nikola; Kariyawasam, Viraj C. 
2021Early thiopurine maintenance and reduced colectomy rate in ulcerative colitis: fact or fiction?Mourad, F. H.; Leong, R. W.; Kariyawasam, Viraj C.; Kariyawasam, Viraj C. 
2022Histological remission using a Nancy Index of 0 is associated with longer relapse-free survival than histological activity in patients with ulcerative colitis in clinical and endoscopic remissionPudipeddi, A.; Fung, C.; Kariyawasam, Viraj C.; Paramsothy, R.; Ghaly, S.; Haifer, C.; An, Y.; Begun, J.; Connor, S.; Chetwood, J.; Paramsothy, S.; Leong, R.; Kariyawasam, Viraj C. 
2022Impact of cytomegalovirus on outcomes in acute severe ulcerative colitisHuang, Dazhong; Rennie, M.; Nikola, M.; Liu, L. S.; Ge, E.; Khehra, Barinder; Nagubandi, Shyam; Au, Michael; Kariyawasam, Viraj C.; Huang, Dazhong; Rennie, M.; Nikola, M.; Liu, L. S.; Ge, E.; Khehra, Barinder; Nagubandi, Shyam; Au, Michael; Kariyawasam, Viraj C. 
2025On being on the same page: Predictors of gastroenterologist-patient misalignment in inflammatory bowel diseaseKarimi, N.; Moore, A. R.; Jones, A.; Lukin, A.; Pipicella, J. L.; Williams, A. J.; Ng, W.; Kanazaki, R.; Kariyawasam, Viraj C.; Mitrev, Nikola; Pandya, Keval V.; Andrews, J. M.; Connor, S. J.; Kariyawasam, Viraj C.; Mitrev, Nikola; Pandya, Keval V. 
2022Post-induction IL-12/23 levels correlate with clinical response and remission after ustekinumab in a multicenter prospective cohort study of patients with Crohn's disease: Preliminary induction results of the AURORA study, including the Australia New Zealand IBD Consortium CohortAn, Y. K.; Lindsay, N.; Allan, N.; Khoo, E.; Amiss, A.; Moniruzzaman, M.; Fernandes, R.; Ooi, S. Y.; Thin, L.; Lightowler, D.; Connor, S.; Williams, A. J.; De Cruz, P.; Li Wai Suen, C.; Kariyawasam, Viraj C.; Mitrev, Nikola; Ghaly, S.; Andrews, J. M.; Christensen, B.; Sparrow, M.; White, L.; Bryant, R. V.; Ding, N.; Leong, R.; Van Langenberg, D.; Seltenreich, H.; Subramaniam, K.; Radford-Smith, G.; Begun, J.; Kariyawasam, Viraj C.; Mitrev, Nikola 
2023Post-ustekinumab induction IL12, IL23, and ustekinumab levels are associated with clinical response in a multi-centre prospective cohort study of Crohn's disease patients: Results from the AURORA Study including ANZIBDC CohortAn, Y. K.; Lindsay, N.; Allan, N.; Khoo, E.; Fernandes, R.; Amiss, A.; Pham, H.; Wong, K. F.; Ooi, S. Y.; Thin, L.; Lightowler, D.; Connor, S. J.; Williams, A. J.; De Cruz, P.; Li Wai Suen, C.; Kariyawasam, Viraj C.; Mitrev, Nikola; Ghaly, S.; Andrews, J. M.; Christensen, B.; Sparrow, M. P.; White, L. S.; Bryant, R. V.; Ding, N.; Leong, R.; Van Langenberg, D.; Seltenreich, H.; Subramaniam, K.; Radford-Smith, G.; Begun, J.; Kariyawasam, Viraj C.; Mitrev, Nikola 
Mitrev-2021-Review of exclusive enteral therap.pdf.jpg2021Review of exclusive enteral therapy in adult Crohn's diseaseMitrev, Nikola; Huang, H.; Hannah, Barbara; Kariyawasam, Viraj C.; Mitrev, Nikola; Hannah, Barbara; Kariyawasam, Viraj C. 
Mitrev-2020-Review of therapeutic drug monitor.pdf.jpg2020Review of therapeutic drug monitoring of infliximab in spondyloarthritis-Catching up with management concepts from other inflammatory conditionsMitrev, Nikola; Kariyawasam, Viraj C.; Mitrev, Nikola; Kariyawasam, Viraj C. 
Au-2021-Safety of dual biological therapy in a.pdf.jpg2021Safety of dual biological therapy in a patient receiving ocrelizumab for multiple sclerosis and vedolizumab for Crohn's disease: A case report and literature review updateAu, Michael; Mitrev, Nikola; Leong, R.; Kariyawasam, Viraj C.; Au, Michael; Mitrev, Nikola; Kariyawasam, Viraj C. 
2023Superior treatment persistence with ustekinumab in biologic-experienced luminal Crohn's disease: Real-world registry data from the Persistence Australian National IBD Cohort (PANIC) studyChetwood, J.; Ko, Y.; Pudipeddi, A.; Kariyawasam, Viraj C.; Paramsothy, S.; Leong, R.; Kariyawasam, Viraj C. 
Sanagapalli-2018-The association between new g.pdf.jpg2018The association between new generation oral contraceptive pill and the development of inflammatory bowel diseasesSanagapalli, S.; Ko, Y.; Kariyawasam, Viraj C.; Ng, S. C.; Tang, W.; Silva, H. J.; Chen, M.; Wu, K.; Aniwan, S.; Ng, K. K.; Ong, D.; Ouyang, Q.; Hilmi, I.; Simadibrata, M.; Pisespongsa, P.; Gopikrishna, S.; Leong, R. W.; Kariyawasam, Viraj C. 
2025Vedolizumab serum trough concentrations with and without thiopurines in ulcerative colitis: The prospective VIEWS pharmacokinetics studyChaemsupaphan, T.; Pudipeddi, A.; Lin, H. Y.; Paramsothy, S.; Kariyawasam, Viraj C.; Kermeen, M.; Leong, R. W.; Kariyawasam, Viraj C. 
-Viraj C. KariyawasamKariyawasam, Viraj C.